Edgewise Therapeutics announces six sites are open for enrollment for the Canyon trial

We are pleased to announce that six sites are open for enrollment for the Canyon trial for individuals living with Becker Muscular Dystrophy! Canyon is a Phase 2 trial of EDG-5506 to evaluate safety, tolerability, biomarkers of muscle damage and changes in functional measures in adolescents and men with Becker muscular dystrophy. As more sites continue to open across the US, we will update the community. SEE MORE HERE: